Blueprint Medicines (NASDAQ:BPMC) Cut to Hold at Citizens Jmp
Citizens Jmp downgraded shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) from a strong-buy rating to a hold rating in a report issued on Tuesday,Zacks.com reports. Several other brokerages have also issued reports on BPMC. Wedbush reissued a “neutral” rating and issued a $129.00 price target (up previously from $128.00) on shares of Blueprint Medicines […]
Citizens Jmp downgraded shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) from a strong-buy rating to a hold rating in a report issued on Tuesday,Zacks.com reports. Several other brokerages have also issued reports on BPMC. Wedbush reissued a “neutral” rating and issued a $129.00 price target (up previously from $128.00) on shares of Blueprint Medicines […]
